AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

2.17M

Current Price

$0.06
+0.000 (+0.000%)

Book Price

$-0.18
Overvalued by 416.63%
Financial Institution

Company Metrics

  • P/E 0.707
  • P/S 51.773
  • P/B 0.42
  • EPS 0.082
  • Dividend 0 / 0%
  • Avg. Vol. 27,260.00
  • Shares 37.41M
  • Market Cap. 2.17M

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
To elaborate - some years ago, AFFY was one of the more promising biotech companies on the OTC. It had intellectual property, strong partners, funded its operations successfully, and even managed to deliver a product on the market.
Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax: Putting The Pieces Together
Seeking Alpha - Aug 24, 2013
Affymax's sole drug product is OMONTYS┬« (peginesatide) Injection ("OMONTYS"), which was approved by the FDA in 2012 and well received by the medical community as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on ...
Affymax, Inc. (NASDAQ:AFFY) Stock Shoots Up
HotStocked - Aug 9, 2010
On the next day, investors unlocked the upward potential of AFFY stock. Additional impact on the stock rush had the company's announcement about some strategic plans of Affymax and Takeda to collaborate on the development and co-commercialization of ...
Affymax stock plunges 85 percent on drug recall
Reuters - Feb 25, 2013
Shares of Affymax Inc AFFY.O fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of ... - Business Wire (press release)
Affymax Board Announces Decision to Dissolve the Company
Business Wire (press release) - Jun 24, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all ...
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Takeda and Affymax Announce Supply Agreement for OMONTYS ® (peginesatide ...
Business Wire (press release) - Jul 12, 2012
DEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A. (TPUSA) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and ...
Affymax To Pay $6.5M To End Class Action Over Anemia Drug
Law360 (subscription) - Jul 3, 2014
Law360, New York (July 3, 2014, 6:53 PM EDT) -- Biopharmacuetical company Affymax Inc. has agreed to pay $6.5 million to settle a class action alleging it knowingly misled investors about the dangers of its drug Omontys, which was recalled in 2013 ...
Affymax CEO steps down as restructuring firm steps in
San Francisco Business Times (blog) - May 15, 2013
Palo Alto-based Affymax (NASDAQ: AFFY) said it will appoint a Brenner Group representative as CEO "in the coming weeks" and name Brenner Group personnel as company officers.